Proteins



Product Data Sheet

PCSK9 Protein, Human (HEK293, V474I, G670E, His)

Cat. No.: HY-P70545

Synonyms: Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1;

NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1

Species: Human Source: HEK293

Accession: Q8NBP7 (Q31-Q692, V474I, G670E)

Gene ID: 255738 Molecular Weight: 19&60 kDa

PROPERTIES

AA Comuna				
AA Sequence	QEDEDGDYEE	LVLALRSEED	GLAEAPEHGT	TATFHRCAKD
	PWRLPGTYVV	VLKEETHLSQ	SERTARRLQA	QAARRGYLTK
	ILHVFHGLLP	GFLVKMSGDL	LELALKLPHV	DYIEEDSSVF
	AQSIPWNLER	ITPPRYRADE	YQPPDGGSLV	EVYLLDTSIQ
	SDHREIEGRV	MVTDFENVPE	EDGTRFHRQA	SKCDSHGTHL
	AGVVSGRDAG	VAKGASMRSL	RVLNCQGKGT	VSGTLIGLEF
	IRKSQLVQPV	GPLVVLLPLA	GGYSRVLNAA	CQRLARAGVV
	LVTAAGNFRD	DACLYSPASA	PEVITVGATN	AQDQPVTLGT
	LGTNFGRCVD	LFAPGEDIIG	ASSDCSTCFV	SQSGTSQAAA
	HVAGIAAMML	SAEPELTLAE	LRQRLIHFSA	KDVINEAWFP
	EDQRVLTPNL	VAALPPSTHG	AGWQLFCRTV	WSAHSGPTRM
	ATAIARCAPD	EELLSCSSFS	RSGKRRGERM	EAQGGKLVCR
	AHNAFGGEGV	YAIARCCLLP	QANCSVHTAP	PAEASMGTRV
	HCHQQGHVLT	GCSSHWEVED	LGTHKPPVLR	PRGQPNQCVG
	HREASIHASC	CHAPGLECKV	KEHGIPAPQE	QVTVACEEGW
	TLTGCSALPG	TSHVLGAYAV	DNTCVVRSRD	VSTTGSTSEE
	AVTAVAICCR	SRHLAQASQE	L Q	
Biological Activity	The enzyme activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.			
Appearance	Solution.			
Formulation	Supplied as a 0.2 μm filtered solution of 20 mM NaH ₂ PO ₄ , 150mM NaCl, 0.1 M Arginine, 0.1 M Glu, 0.01% Tween20, pH 7.4.			
Endotoxin Level	<1 EU/μg, determined by LAL method.			
Reconsititution	N/A			
Storage & Stability	Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.			

Page 1 of 2 www. Med Chem Express. com Shipping

Shipping with dry ice.

DESCRIPTION

Background

PCSK9 protein emerges as a pivotal regulator in the intricate orchestration of plasma cholesterol homeostasis. Demonstrating its influence on low-density lipid receptor family members, including the low-density lipoprotein receptor (LDLR), very low-density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER), and apolipoprotein receptor 2 (LRP8/APOER2), PCSK9 facilitates their degradation within intracellular acidic compartments. Employing a non-proteolytic mechanism, it enhances the hepatic LDLR degradation through a clathrin LDLRAP1/ARH-mediated pathway, possibly impeding LDLR recycling and directing it toward lysosomal degradation. Moreover, PCSK9 exhibits LDLR-independent inhibition of APOB intracellular degradation via the autophagosome/lysosome pathway and plays a role in the disposal of non-acetylated BACE1 intermediates in the early secretory pathway. Notably, it regulates epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by augmenting ENaC proteasomal degradation, and influences neuronal apoptosis through the modulation of LRP8/APOER2 levels and associated anti-apoptotic signaling pathways.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA